\Box

(Street)

WASHINGTON

DC

20015

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934

OMB APPROVAL							
OMB Number:	3235-0287						
Estimated average burden							

-		
	hours per response:	0.5
	Lounded average builden	

				ection 30(h) of the Ir						·		
1. Name and Addr EDELMAN		BIC	2. Issuer Name and Ticker or Trading Symbol BIOSANTE PHARMACEUTICALS INC [BPA]						lationship of Reporti ck all applicable) Director	X 109	6 Owner	
(Last) (First) (Middle) C/O FIRST NEW YORK SECURITIES 850 THIRD AVENUE, 8TH FLOOR				te of Earliest Transa 6/2004	action (N	1onth/	Day/Year)			Officer (give title below)	belo	er (specify ow)
(Street) NEW YORK NY 10022 (City) (State) (Zip)				vmendment, Date of	Origina	l Filed	(Month/Day/ [\]	Year)	6. Inc Line) X	lividual or Joint/Grou Form filed by Or Form filed by Mo Person	ne Reporting P	erson
		Table I - No	n-Derivative	Securities Acq	uired,	Dis	posed of,	or Ben	eficially	/ Owned		
Date			2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Disposed Of 5)	Acquired (D) (Instr	(A) or 3, 4 and	5. Amount of Securities Beneficially Owned Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Ownership
					Code	v	Amount	(A) or (D)	Price Reported Transaction(s) (Instr. 3 and 4)			(Instr. 4)
Common Stock	(1)		08/16/2004		Р		200	A	\$5.1	7,450	I	FNYT Account ⁽²⁾
Common Stock			08/16/2004		s		200	D	\$5.5	7,250	I	FNYT Account ⁽²⁾
Common Stock										1,768,850	I	Through Master Fund ⁽³⁾

Common	Stock													225,000		D ⁽⁴⁾																																																																																																																																									
		Ta	able II - Deriva (e.g.,							osed of, onvertib				ed																																																																																																																																											
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Trans Code 8)	action (Instr.	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		n of r. Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4		n of r. Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4		n of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4		n of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4		n of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4		n of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4		n of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4		n of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4		n of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4		n of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4		 of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4) 		n of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4		n of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4		n of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4		of of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4		 of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 		n of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4		n of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4		of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4		of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4		 of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 		of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4		of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4		of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4		 of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4) 		n of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4		n of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4		n of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4		6. Date Exercisable ar Expiration Date (Month/Day/Year)		Expiration D		Expiration D e (Month/Day/ s l		Expiration Da (Month/Day/Y) ised 3, 4		Expiration Date (Month/Day/Year)				Expiration Date		Expiration Date		Expiration Date		Expiration Date		of Expiration Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4		of Expiration D Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4		xpiration Date		Expiration Date		xpiration Date Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative		Amount of Securities Underlying Derivative Security (Instr. 3		of 9. Numbe ve derivativ. / Securitie Beneficia Owned Following Reported Transacti (Instr. 4)	e s Illy J	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)																																																				
				Code	v	(A)	(D)	Date Exercisab		Expiration Date	Title	Amount or Number of Shares																																																																																																																																													
	nd Address of	Reporting Person [*]																																																																																																																																																							
		(First) ORK SECURIT JE, 8TH FLOOF																																																																																																																																																							
(Street) NEW Y	ORK	NY	10022																																																																																																																																																						
(City)		(State)	(Zip)																																																																																																																																																						
	EPTIVE I	Reporting Person [*]		<u>R</u>																																																																																																																																																					
(Last) 5437 CO	NNECTIC	(First) UT AVE NW ST	(Middle) TE 100																																																																																																																																																						

(City)	(State)	(Zip)								
1. Name and Address of Reporting Person* <u>PERCEPTIVE ADVISORS LLC</u>										
(Last) (First) (Middle)										
PERCEPTIVE CA	PITAL CUT AVENUE NW	STE 100								
(Street)										
WASHINGTON	DC	20015								
(City)	(State)	(Zip)								
1. Name and Address of <u>Cho Michael</u>	of Reporting Person [*]									
(Last)	(First)	(Middle)								
850 THIRD AVEN	IUE									
21ST FLOOR										
(Street) NEW YORK	NY	10022								
	1 1 1	10022								
(City)	(State)	(Zip)								

Explanation of Responses:

1. This Form 4 is being filed by Joseph Edelman, Michael Cho, Perceptive Life Sciences Master Fund Ltd. ("Master Fund") and Perceptive Advisors LLC ("Advisors").

2. These securities are held in an account of First New York Trading, LLC ("FNYT"). In accordance with Instruction 4(b)(iv) to Form 4, the entire amount of the Issuer's securities held through the FNYT account is reported herein. Each of Mr. Edelman and Mr. Cho disclaims, for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, beneficial ownership of any such securities or with respect to such transactions, as applicable, except to the extent of his indirect pecuniary interest therein, and this report shall not be deemed an admission that Mr. Edelman or Mr. Cho is the beneficial owner of such securities or with respect to such transactions, as applicable, for purposes of Section 16 or for any other purposes. Each of the Master Fund and the Advisors disclaims beneficial ownership, for purposes of Section 16 or for any other purposes. Each of the Master Fund and the Advisors disclaims beneficial ownership, for purposes of Section 16 or for any other purposes.

3. These securities are being held by Master Fund, of which Advisors is the investment advisor. Mr. Edelman is the managing member of Advisors. In accordance with Instruction 4(b)(iv) to Form 4, the entire amount of the Issuer's securities held by Master Fund is reported herein. Each of Mr. Edelman and Advisors disclaims, for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, beneficial ownership of any such securities, except to the extent of its/his indirect pecuniary interest therein, and this report shall not be deemed an admission that Mr. Edelman or Advisors is the beneficial owner of such securities are held directly by Mr. Edelman.

<u>/s/ Joseph Edelman</u>

<u>08/18/2004</u> Date

** Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

- Names: Perceptive Life Sciences Master Fund Ltd., Perceptive Advisors LLC and Michael Cho
- Address: c/o First New York Securities, LLC 850 Third Avenue, 8th Floor New York, New York 10022

Designated Filer:

Joseph Edelman

Issuer and Ticker Symbol:

Biosante Pharmaceuticals, Inc. (BPA)

Date of Earliest Transaction (Month/Day/Year) August 16, 2004

The undersigned, Michael Cho, Perceptive Life Sciences Master Fund Ltd. and Perceptive Advisors LLC are jointly filing the attached Statement of Changes in Beneficial Ownership on Form 4 with Joseph Edelman with respect to the beneficial ownership of securities of Biosante Pharmaceuticals, Inc.

PERCEPTIVE LIFE SCIENCES MASTER FUND LTD.

PERCEPTIVE ADVISORS LLC

By: Perceptive Advisors LLC, its investment advisor

By:	/s/ Joseph	Edelman	By:	/s/	Joseph	Edelman
	Joseph Edel Managing Me				eph Edel aging Me	

/s/ Michael Cho

- -----Michael Cho

Page 3 of 3